Global Cancer Anorexia-Cachexia Syndrome (CACS) Market to Reach $5.84 Billion by 2029, Growing at 10.7% CAGR

What industry-specific factors are fueling the growth of the cancer anorexia-cachexia syndrome (cacs) market?
The increasing prevalence of cancer is expected to drive the growth of the cancer anorexia-cachexia syndrome market. Cancer is a group of diseases characterized by uncontrolled cell growth and spread, and cancer rates are rising globally due to an aging population, lifestyle changes, environmental factors, improved detection methods, and increased awareness. Cancer anorexia-cachexia syndrome (CACS) addresses the growing cancer prevalence by focusing on managing the severe weight loss and malnutrition common in cancer patients, improving their quality of life and treatment outcomes. For instance, in August 2024, Macmillan Cancer Support reported that over 3 million people in the UK are living with cancer, and this number is expected to grow to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Thus, the increasing cancer prevalence is propelling the growth of the cancer anorexia-cachexia syndrome market.

Get Your Cancer Anorexia-Cachexia Syndrome (CACS) Market Report Here:
https://www.thebusinessresearchcompany.com/report/cancer-anorexia-cachexia-syndrome-cacs-global-market-report

What Is the projected market size and growth rate for the cancer anorexia-cachexia syndrome (cacs) market?
The cancer anorexia-cachexia syndrome (CACS) market has grown rapidly, expected to expand from $3.51 billion in 2024 to $3.89 billion in 2025 at a CAGR of 11.0%. Factors contributing to past growth include the rising incidence of cancer, increased awareness among healthcare professionals, a growing focus on improving cancer patients' quality of life, expansion of clinical trials, and partnerships within the pharmaceutical sector.

The cancer anorexia-cachexia (CACS) market is expected to experience rapid expansion in the coming years, reaching $5.84 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%. This growth is driven by improved cancer survival rates, increased investments in oncology supportive care, advancements in personalized medicine, a growing emphasis on multimodal therapies, and the expansion of healthcare infrastructure. Key trends anticipated during this period include progress in palliative care, the development of targeted treatments, innovations in drug delivery systems, AI integration in drug development, and advancements in personalized medicine.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

What new trends are reshaping the cancer anorexia-cachexia syndrome (cacs) market and its opportunities?
In the cancer anorexia-cachexia syndrome market, companies are developing monoclonal antibody therapies to improve treatment efficacy and address unmet clinical needs. For example, in September 2024, Pfizer Inc., a U.S.-based pharmaceutical company, announced positive Phase II trial results for ponsegromab, a monoclonal antibody targeting GDF-15. The trial demonstrated significant progress in reducing inflammation and muscle loss in cancer patients suffering from anorexia-cachexia syndrome, providing hope for a new treatment option for this debilitating condition.

What major market segments define the scope and growth of the cancer anorexia-cachexia syndrome (cacs) market?
The cancer anorexia-cachexia syndrome (CACS) market covered in this report is segmented -

1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Transdermal, Other Route of Administration
5) By Application: Hospitals, Clinics, Home Care

Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21125

Which region dominates the cancer anorexia-cachexia syndrome (cacs) market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (CACS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the cancer anorexia-cachexia syndrome (cacs) industry growth?
Major companies operating in the cancer anorexia-cachexia syndrome (CACS) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp

What Is Covered In The Cancer Anorexia-Cachexia Syndrome (CACS) Global Market Report?

•Market Size Forecast: Examine the cancer anorexia-cachexia syndrome (cacs) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the cancer anorexia-cachexia syndrome (cacs) market for a structured understanding.
•Key Players Overview: Analyze major players in the cancer anorexia-cachexia syndrome (cacs) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the cancer anorexia-cachexia syndrome (cacs) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the cancer anorexia-cachexia syndrome (cacs) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the cancer anorexia-cachexia syndrome (cacs) market.
•Industry Challenges: Identify potential risks and obstacles affecting the cancer anorexia-cachexia syndrome (cacs) market.
•Competitive Landscape: Review strategic developments in the cancer anorexia-cachexia syndrome (cacs) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.